Perimeter Medical Imaging AI places Claire at hospitals while recurring legacy revenue rises 31%

Perimeter Medical Imaging AI, Inc. (TSXV: PINK; OTCQX: PYNKF) has reached an important transition point in the commercialization of its artificial intelligence-enabled Claire OCT System: hospitals have begun placing and using the newly FDA-approved device, but its second-quarter revenue was still generated entirely by the older S-Series platform. Preliminary revenue for the three months ended June 30 was approximately US$503,000, up 31% sequentially from about US$385,000, with the full amount coming from recurring consumable sales, system leases, maintenance and warranty programmes linked to the legacy system.

That creates a useful dividing line between regulatory and commercial progress. The U.S. Food and Drug Administration granted premarket approval to Claire on March 3, 2026 for adjunctive real-time imaging and artificial intelligence-assisted identification of suspicious areas in excised lumpectomy tissue during breast-conserving surgery. Perimeter subsequently secured its first two commercial placements during the second quarter and, in August, Intermountain Health became the first U.S. health system to commercially deploy Claire in the operating room.

The next financial test is therefore whether those placements translate into a recurring-revenue stream large enough to change the scale of a company that still generated only about half a million dollars of quarterly revenue.

How much did Perimeter Medical Imaging AI improve its Q2 cost structure?

Preliminary operating expenses fell 28% year over year to approximately US$3.1 million from US$4.3 million. The quarterly net loss narrowed by about one-third to US$2.6 million, or US$0.02 per share, compared with approximately US$3.9 million, or US$0.04 per share, during the second quarter of 2025.

Cash used in operating activities during the first six months of 2026 declined 23% to approximately US$5.1 million. Perimeter held around US$6.4 million of cash at June 30, meaning the balance sheet still requires careful management as commercialization spending continues, even though operating losses and cash consumption have improved.

The company supplemented its resources through two financing transactions. Its listed issuer financing exemption offering ultimately issued 21.489 million units at C$0.35 each for gross proceeds of about C$7.52 million, while a separate private placement generated C$6.04 million of 3.59% convertible debentures. Combined, the two transactions represent approximately C$13.56 million of gross equity and convertible-debt financing, although the instruments have different economics and should not be treated as equivalent forms of capital.

The improved expense base becomes particularly relevant because Claire’s commercial launch will require sales support, training, installation and continued product infrastructure before the platform produces enough recurring revenue to absorb those costs.

What has changed since Claire received FDA premarket approval?

Claire combines optical coherence tomography with an artificial intelligence computer-aided detection algorithm. The FDA-approved indication allows the system to provide three-dimensional, cross-sectional visualization of excised lumpectomy tissue while flagging focal areas suspicious for breast cancer for concurrent physician interpretation. It is an adjunct to other margin-evaluation methods and does not replace histopathology or function as a standalone diagnostic test.

The March approval shifted Perimeter from development and regulatory execution into commercialization. By late May, the company had announced its first two commercial Claire placements, both replacing existing S-Series systems at hospitals, while management said the sales funnel had expanded to close to 50 qualified leads. More than a dozen of those opportunities were described as having advanced beyond the earliest sales stage.

The commercial milestone broadened in August when Intermountain Health became the first U.S. health system to deploy Claire commercially for real-time margin assessment during breast-conserving surgery. That provides Perimeter with a reference installation within a major nonprofit health network rather than only a regulatory approval and sales pipeline.

However, the second-quarter revenue composition shows that clinical adoption and reported financial contribution are not yet the same thing. None of the approximately US$503,000 of Q2 revenue was identified as Claire revenue, making subsequent quarters more informative about the pace at which the new platform converts installations into consumables, leases, service revenue or system sales.

Why could recurring revenue matter more than the first Claire placements?

Perimeter’s existing S-Series business demonstrates part of the intended model. Its second-quarter revenue came entirely from recurring sources including consumables, leases, maintenance and extended-service programmes, and that recurring revenue increased 31% sequentially.

If Claire can develop a similar installed-base model at a much larger scale, each hospital placement could create an ongoing revenue relationship rather than a one-time equipment sale. That is especially relevant for a small medical-device company because predictable recurring revenue can help offset the cost of maintaining a direct commercial organization.

The opportunity should nevertheless be separated from the regulatory claim. FDA approval establishes that Claire can be marketed for its approved indication in the United States; it does not establish the speed of hospital purchasing, reimbursement economics, surgeon adoption or eventual market share.

Perimeter has crossed several of the hardest technical milestones by obtaining PMA approval, launching Claire and securing its first commercial deployments. The financial milestone is still ahead. After a quarter in which every dollar of revenue continued to come from the legacy S-Series platform, the clearest evidence of successful commercialization will be the point at which Claire starts materially changing the company’s revenue trajectory rather than simply its product story.